Ewing sarcoma of bone
MONDO:0002625A small round cell bone tumor that lacks morphologic, immunohistochemical, and electron microscopic evidence of neuroectodermal differentiation. It represents one of the two ends of the spectrum called Ewing sarcoma/peripheral neuroectodermal tumor. It often affects the diaphysis or metaphyseal-diaphyseal portion of long bones. Clinical findings include pain and a mass in the involved area. fever, anemia, leukocytosis, and an increased sedimentation rate are often seen. X-ray examination reveals osteolytic lesions. The prognosis depends on the stage, anatomic location, and size of the tumor.
Also known as: Ewing sarcoma of bone, Ewing's sarcoma of bone, Ewing's sarcoma, osseous, Ewing's sarcoma/bone peripheral primitive neuroectodermal tumour, bone Ewing's sarcoma, bone localised Ewing sarcoma, bone localised Ewing's sarcoma, bone tissue Ewing sarcoma
2785 clinical trials for this condition and its sub-types, 5 tagged with Ewing sarcoma of bone itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New hope for young bone cancer patients: drug combo targets tough tumors
Disease control CompletedThis study tests the drug regorafenib in 30 patients aged 9 to 21 with bone cancers (osteosarcoma or Ewing sarcoma) that have not responded to standard therapy. The goal is to see if the drug can help control the disease and improve survival, while also checking its safety. The a…
Phase 1/2 • Sponsor: Institute of Mother and Child, Warsaw, Poland • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Cancer drug regorafenib tested to halt bone sarcoma spread
Disease control CompletedThis phase 2 trial tests whether the drug regorafenib can stop or slow the growth of metastatic bone sarcomas (cancers that started in bone and spread). 163 patients with osteosarcoma, Ewing sarcoma, chondrosarcoma, or chordoma are randomly assigned to receive regorafenib or a pl…
Phase 2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC